ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION?

Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic ev...

Full description

Saved in:
Bibliographic Details
Main Authors: D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
Format: Article
Language:English
Published: Столичная издательская компания 2016-05-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/1238
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic events) are discussed. The authors briefly present subanalysis of ARISTOTLE study, which compares the efficacy and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic heart disease.
ISSN:1819-6446
2225-3653